I. Atherosclerosis And Cardiovascular Disease -- 1. PPAR-Alpha in Lipid and Lipoprotein Metabolism, Vascular Inflammation and Atherosclerosis -- 2. The Choice of an Appropriate Animal Species in the Study of Chlamydia pneumoniae as an Atherogenic Agent -- 3. Endothelial Cell Dysfunctionโ{128}{148}A Key Factor in Atherogenesis and its Reversal (Laboratory and Clinical Study) -- 4. Biochemical Mechanisms of Hyperhomocysteinemia in Atherosclerosis: Role of Chemokine Expression -- 5. Oxyradicals and Hypercholesterolemic Atherosclerosis -- 6. Identification, Regulation and Function of LOX-1, A Novel Receptor for Ox-LDL -- 7. Atherosclerosis and Angiotensin II in Hypercholesterolemia and Diabetes. A Role for ATt Receptors Beyond Hypertension -- 8. Basic and Clinical Results of New Statin: Pitavastatin -- 9. Reducing Cardiovascular Risk With HMG CoA Reductase Inhibitors, Potential Contribution From Platelets -- 10. Rapamycin-Sensitive Signal Transduction Pathways and the Control of Adipogenesis -- II. Hypertension -- 11. Genetic Predisposition to Hypertension and Cardiovascular Disease -- 12. Role of Sympathetic Nervous System in Hypertension -- 13. Role of Hypothalamic Peptides in the Development of Hypertension -- 14. Myosin Light Chain Kinase in Endothelial Cell Calcium Signaling and Endothelial Functions -- 15. Sarpogrelate Inhibits Genes Involved in Vascular Neointimal Hyperplasia and Remodeling -- 16. A Nutritional Approach to Prevent High Blood Pressure -- 17. Cardiovascular and Renal Actions of Leptin -- 18. Brain Na, K-ATPase Enzymatic Activity and Cardiovascular Regulation -- 19. Development of Transdermal and Transbuccal Drug Delivery Systems for Cardioactive Drugs with Special Reference to Anti-Hypertensive Agents -- 20. Insulin Resistance and Experimental Hypertension -- III. Diabetes Mellitus -- 21. New Paradigm for Insulin Resistance: The HISS Story -- 22. Vanadium Effects in Diabetes -- 23. Dyslipoproteinemia and Fibrinolysis -- 24. Endothelins and Cardiovascular Disease in Diabetes -- 25. Usefulness of 5-HT2A Receptor Antagonists for the Treatment of Cardiovascular Complications in Diabetes -- 26. Selective Attenuation of Enhanced Angiotensin II Mediated Responses in the Streptozotocin Diabetic Rat Thoracic Aorta by Tempol -- 27. Role of Renin-Angiotensin System in Diabetic Heart Dysfunction and Changes in Phospholipase C Activity -- 28. Regulation of Cardiac Function in Diabetes -- 29. Diabetes and Cardiac Dysfunction -- 30. Mechanisms Underlying Contractile Dysfunction in Streptozotocin-Induced Type 1 and Type 2 Diabetic Cardiomyopathy -- 31. Protein Kinase C Signaling and Expression of the Diabetic Cardiac Phenotype -- 32. Oxidative Stress in Cardiovascular Complications of Diabetes -- 33. Augmented Energy Transfer in Rat Heart Mitochondria: Compensatory Response to Abnormal Household of Energy in Acute Diabetes -- 34. Ketosis, Tumor Necrosis Factor-a and Cardiovascular Disease in Type-1 Diabetic Patients -- 35. Epigenetic Alterations in Diabetic Cardiomyopathy